Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-iT infection prophylaxis in total joint replacement
2024-515055-38-00Phase 3Authorised
- Sponsor
- Hamilton Health Sciences
- Start
- Feb 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial of vancomycin, chlorhexidine, povidone, benzalkonium chloride and benzyl alcohol in None and periprosthetic joint infection (PJI) (2 arms), sponsored by Hamilton Health Sciences. Primary endpoint: Infection requiring reoperation within 12 months of total joint replacement. Planned start Feb 2025; status: authorised.
02
Drugs
vancomycinchlorhexidinepovidonebenzalkonium chloridebenzyl alcohol
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-515055-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515055-38-00.